Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety.

In vitro transcribed mRNA constitutes a versatile platform to encode antigens and to evoke CD8 T-cell responses. Systemic delivery of mRNA packaged into cationic liposomes (lipoplexes) has proven particularly powerful in achieving effective antitumor immunity in animal models. Yet, T-cell responses to mRNA lipoplexes critically depend on the induction of type I interferons (IFN), potent pro-inflammatory cytokines, which inflict dose-limiting toxicities. Here, we explored an advanced hybrid lipid polymer shell mRNA nanoparticle (lipopolyplex) endowed with a trimannose sugar tree as an alternative delivery vehicle for systemic mRNA vaccination. Like mRNA lipoplexes, mRNA lipopolyplexes were extremely effective in conferring antitumor T-cell immunity upon systemic administration. Conversely to mRNA lipoplexes, mRNA lipopolyplexes did not rely on type I IFN for effective T-cell immunity. This differential mode of action of mRNA lipopolyplexes enabled the incorporation of N1 methyl pseudouridine nucleoside modified mRNA to reduce inflammatory responses without hampering T-cell immunity. This feature was attributed to mRNA lipopolyplexes, as the incorporation of thus modified mRNA into lipoplexes resulted in strongly weakened T-cell immunity. Taken together, we have identified lipopolyplexes containing N1 methyl pseudouridine nucleoside modified mRNA as potent yet low-inflammatory alternatives to the mRNA lipoplexes currently explored in early phase clinical trials.

[1]  M. Monsigny,et al.  Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. , 1988, Analytical biochemistry.

[2]  M. Monsigny,et al.  Efficient gene transfer by histidylated polylysine/pDNA complexes. , 1999, Bioconjugate chemistry.

[3]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[4]  Feng Liu,et al.  Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. , 2005, Advanced drug delivery reviews.

[5]  H. Fehling,et al.  Faithful activation of an extra‐bright red fluorescent protein in “knock‐in” Cre‐reporter mice ideally suited for lineage tracing studies , 2007, European journal of immunology.

[6]  B. Ryffel,et al.  mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes , 2007, Cancer Gene Therapy.

[7]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  C. Pichon,et al.  Synthesis and Transfection Activity of New Cationic Phosphoramidate Lipids: High Efficiency of an Imidazolium Derivative , 2008, Chembiochem : a European journal of chemical biology.

[10]  K. Rajewsky,et al.  Novel Reporter Mouse Reveals Constitutive and Inflammatory Expression of IFN-β In Vivo1 , 2009, The Journal of Immunology.

[11]  Philip C. Bevilacqua,et al.  Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation , 2010, Nucleic acids research.

[12]  F. Belardelli,et al.  Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity , 2010, Autoimmunity.

[13]  G. Splitter,et al.  Antigen specific killing assay using CFSE labeled target cells. , 2010, Journal of visualized experiments : JoVE.

[14]  D. Weissman,et al.  Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L , 2011, Nucleic acids research.

[15]  D. Weissman,et al.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA , 2011, Nucleic acids research.

[16]  C. Pichon,et al.  Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[17]  Douglas A. Lauffenburger,et al.  Polyfunctional responses by human T cells result from sequential release of cytokines , 2011, Proceedings of the National Academy of Sciences.

[18]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[19]  C. Heirman,et al.  Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. , 2012, Cancer research.

[20]  Ansuman T. Satpathy,et al.  Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination , 2012, Proceedings of the National Academy of Sciences.

[21]  D. Weissman,et al.  Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Yuhua Wang,et al.  Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Ronald A. Li,et al.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction , 2013, Nature Biotechnology.

[24]  J. Donovan,et al.  Structural basis for cytosolic double-stranded RNA surveillance by human oligoadenylate synthetase 1 , 2013, Proceedings of the National Academy of Sciences.

[25]  Steffen Jung,et al.  Development and function of dendritic cell subsets. , 2014, Immunity.

[26]  B. Neyns,et al.  Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula , 2014, Cancer Immunology, Immunotherapy.

[27]  M. Crow.  Type I Interferon in the Pathogenesis of Lupus , 2014, The Journal of Immunology.

[28]  Shimeng Liu,et al.  Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. , 2014, Nanomedicine.

[29]  C. Pichon,et al.  Lipopolyplexes comprising imidazole/imidazolium lipophosphoramidate, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection. , 2014, International journal of pharmaceutics.

[30]  R. Weiss,et al.  N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[31]  C. Heirman,et al.  Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. , 2016, Molecular therapy. Nucleic acids.

[32]  J. Aerts,et al.  Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours , 2016, Scientific Reports.

[33]  M. Schreckenberger,et al.  Toll like receptor mediated immune stimulation can be visualized in vivo by [18F]FDG-PET. , 2016, Nuclear medicine and biology.

[34]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[35]  V. Koteliansky,et al.  Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside , 2016, International journal of nanomedicine.

[36]  Daniel G. Anderson,et al.  Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. , 2016, Biomaterials.

[37]  C. Pichon,et al.  Synthesis of a trimannosylated-equipped archaeal diether lipid for the development of novel glycoliposomes. , 2016, Carbohydrate research.

[38]  B. Malaekeh-Nikouei,et al.  Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Özlem Türeci,et al.  Elimination of large tumors in mice by mRNA-encoded bispecific antibodies , 2017, Nature Medicine.

[40]  C. Heirman,et al.  Adjuvant-Enhanced mRNA Vaccines. , 2017, Methods in molecular biology.

[41]  I. Verma,et al.  Systemic delivery of factor IX messenger RNA for protein replacement therapy , 2017, Proceedings of the National Academy of Sciences.

[42]  N. Sonenberg,et al.  N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density , 2017, Nucleic acids research.

[43]  R. Hajjar,et al.  Optimizing Cardiac Delivery of Modified mRNA. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  Silvia Stockinger,et al.  Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology , 2017, Front. Immunol..